These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 8395751)

  • 1. Use of octreotide acetate for control of symptoms in patients with islet cell tumors.
    Maton PN
    World J Surg; 1993; 17(4):504-10. PubMed ID: 8395751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors.
    Maton PN
    Gastroenterol Clin North Am; 1989 Dec; 18(4):897-922. PubMed ID: 2559036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
    Maton PN; Gardner JD; Jensen RT
    Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
    Gorden P; Comi RJ; Maton PN; Go VL
    Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
    Wynick D; Bloom SR
    J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).
    Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG
    Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting somatostatin analogues in pancreatic islet cell carcinoma.
    Souquet JC
    Horm Res; 1989; 32(1-3):74-6. PubMed ID: 2559020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
    Trendle MC; Moertel CG; Kvols LK
    Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide--a synthetic somatostatin.
    Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
    Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
    Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
    Ben Yosef R; Glaser B; Catane R
    Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).
    Wynick D; Anderson JV; Williams SJ; Bloom SR
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):385-8. PubMed ID: 2557179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.
    Kraenzlin ME; Ch'ng JL; Wood SM; Carr DH; Bloom SR
    Gastroenterology; 1985 Jan; 88(1 Pt 1):185-7. PubMed ID: 2856877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin analogue therapy in functioning neuroendocrine gut tumors.
    Debas HT; Gittes G
    Digestion; 1993; 54 Suppl 1():68-71. PubMed ID: 8359571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide, a new somatostatin analogue.
    Katz MD; Erstad BL
    Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Islet cell tumors of the pancreas: the medical oncologist's perspective.
    Brentjens R; Saltz L
    Surg Clin North Am; 2001 Jun; 81(3):527-42. PubMed ID: 11459269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Islet cell tumors.
    Stabile BE
    Gastroenterologist; 1997 Sep; 5(3):213-32. PubMed ID: 9298376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma.
    Koelz A; Kraenzlin M; Gyr K; Meier V; Bloom SR; Heitz P; Stalder H
    Gastroenterology; 1987 Feb; 92(2):527-31. PubMed ID: 2878857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Neuhaus C; Benning R; Schwerk WB; Trautmann ME; Joseph K; Bruns C
    World J Surg; 1993; 17(4):511-9. PubMed ID: 8395752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogue SMS 201-995 long term therapy for vipoma.
    Juby LD; Burke DA; Axon AT
    Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.